Yu-Waye Chu Sells 21,279 Shares of CytomX Therapeutics (NASDAQ:CTMX) Stock

CytomX Therapeutics, Inc. (NASDAQ:CTMX) insider Yu-Waye Chu sold 21,279 shares of CytomX Therapeutics stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $6.42, for a total value of $136,611.18. Following the completion of the sale, the insider directly owned 189,446 shares in the company, valued at $1,216,243.32. This represents a 10.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

CytomX Therapeutics Price Performance

NASDAQ CTMX traded up $0.37 during mid-day trading on Thursday, hitting $4.77. The stock had a trading volume of 13,412,791 shares, compared to its average volume of 11,334,038. The firm’s 50 day moving average is $5.28 and its 200 day moving average is $4.10. The stock has a market capitalization of $810.96 million, a price-to-earnings ratio of -119.13 and a beta of 2.44. CytomX Therapeutics, Inc. has a twelve month low of $0.40 and a twelve month high of $8.21.

CytomX Therapeutics (NASDAQ:CTMX) last announced its earnings results on Monday, March 16th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.14). The business had revenue of $0.66 million for the quarter, compared to analyst estimates of $7.33 million. CytomX Therapeutics had a negative return on equity of 19.77% and a negative net margin of 22.79%. As a group, equities research analysts expect that CytomX Therapeutics, Inc. will post -0.05 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Guggenheim upped their price target on CytomX Therapeutics from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Wednesday. Piper Sandler boosted their price objective on CytomX Therapeutics from $6.50 to $10.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 20th. Barclays upped their target price on CytomX Therapeutics from $10.00 to $16.00 and gave the company an “overweight” rating in a report on Thursday. Oppenheimer reiterated an “outperform” rating and set a $12.00 price target on shares of CytomX Therapeutics in a report on Monday. Finally, JPMorgan Chase & Co. raised shares of CytomX Therapeutics from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $7.00 to $12.00 in a research report on Monday. Nine analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $13.22.

Key Headlines Impacting CytomX Therapeutics

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Several brokerages raised ratings/targets, boosting sentiment — Barclays raised its target to $16 (overweight). Article Title
• Positive Sentiment: Guggenheim increased its price target to $15 and kept a Buy rating, supporting upside expectations. Article Title
• Positive Sentiment: Wedbush raised its price target to $11, and JPMorgan reportedly upgraded the stock — multiple upgrades are driving positive analyst momentum. Wedbush Article JPMorgan Article
• Neutral Sentiment: HC Wainwright cut near‑term EPS forecasts (Q1–Q4 2026 and FY2026/2027) but retained a Buy rating and a $17 target — mixed signal (lowered estimates but continued bullish view). MarketBeat Report
• Neutral Sentiment: Short-interest data in the feed appears anomalous (shows zero shares) and likely does not provide meaningful directional signal today.
• Negative Sentiment: CytomX priced an underwritten offering of common stock and pre‑funded warrants to raise up to $250M gross (closing expected March 19); markets often view such equity raises as dilutive, which can pressure the stock despite providing runway for trials. Offering Release
• Negative Sentiment: Related coverage notes net proceeds of about $234M from the offering — confirms material dilution magnitude and why some traders sold into the raise. TipRanks Article
• Negative Sentiment: Insider selling: CFO Christopher Ogden sold 19,323 shares and SVP Marcia Belvin sold 31,492 shares on March 17 — disclosed on SEC Form 4 filings; insider sales can be read negatively by the market. CFO Form 4 SVP Form 4
• Negative Sentiment: Recent quarterly results missed expectations (EPS and revenue), which was cited as a reason for an intra‑day pullback earlier this week. Earnings Reaction

Institutional Trading of CytomX Therapeutics

Several institutional investors have recently made changes to their positions in CTMX. Farther Finance Advisors LLC purchased a new position in CytomX Therapeutics in the third quarter worth approximately $25,000. Wells Fargo & Company MN raised its position in CytomX Therapeutics by 83.2% in the fourth quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 3,000 shares during the period. Invesco Ltd. purchased a new stake in CytomX Therapeutics in the second quarter valued at $32,000. Pursue Wealth Partners LLC acquired a new position in shares of CytomX Therapeutics in the 2nd quarter valued at $33,000. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new position in shares of CytomX Therapeutics in the 3rd quarter valued at $34,000. Hedge funds and other institutional investors own 67.77% of the company’s stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.